论文部分内容阅读
急性心肌梗死(AMI)时,链激酶和组织型纤溶酶原激活剂(t-PA)的相对效果,以及作为辅助疗法的静脉和皮下给予肝素的比较,是尚未解决的问题。本试验旨在比较用标准溶栓方案以新的、积极溶栓决策治疗AMI。对象和方法北美、欧洲、以色列、澳大利亚和新西兰的15个国家1081所医院共41021例AMI患者,发病至入院<6小时、胸痛持续至少20分钟、心电图有≥2个肢导联ST段抬高≥0.1mV或≥2
Acute myocardial infarction (AMI), the relative effect of streptokinase and tissue-type plasminogen activator (t-PA), and the comparison of intravenous and subcutaneous heparin as an adjuvant therapy is an unsolved problem. This trial was designed to compare AMI with a new, aggressive thrombolysis strategy using a standard thrombolysis regimen. Subjects and Methods A total of 41021 AMI patients from 1081 hospitals in 15 countries of North America, Europe, Israel, Australia and New Zealand were admitted to hospital for <6 hours, chest pain sustained for at least 20 minutes, and electrocardiogram had ≥2 lead ST-segment elevation ≥0.1mV or ≥2